Volume 19 Issue 4
Apr.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(4): 572-576
FENG Hui-xin, YANG Yan-li, GENG Ying-hua. Immunophenotype and clinical characteristics of acute myeloid leukaemia with positive FLT3-ITD[J]. Chinese Journal of General Practice, 2021, 19(4): 572-576. doi: 10.16766/j.cnki.issn.1674-4152.001864
Citation: FENG Hui-xin, YANG Yan-li, GENG Ying-hua. Immunophenotype and clinical characteristics of acute myeloid leukaemia with positive FLT3-ITD[J]. Chinese Journal of General Practice, 2021, 19(4): 572-576. doi: 10.16766/j.cnki.issn.1674-4152.001864
shu

Immunophenotype and clinical characteristics of acute myeloid leukaemia with positive FLT3-ITD

doi: 10.16766/j.cnki.issn.1674-4152.001864

  • Department of Haematology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0375

 BYKF1885

 Byycxz1919

  • Received Date: 2020-05-29
    Available Online: 2022-02-16
    Abstract
  •   Objective  To explore the immunophenotype and clinical characteristics of patients with acute myeloid leukaemia (AML) with fms-like tyrosine kinase 3-internal tandem replication (FLT3-ITD) mutation.  Methods  A total of 103 patients with AML (excluding the M3 type), including 24 patients with FLT3-ITD+ (positive group) and 79 patients with FLT3-ITD- (negative group), who were initially diagnosed in the haematology department of the First Affiliated Hospital of Bengbu Medical College from December 2016 to December 2018 were enrolled in this study. The clinical haematological characteristics and immunophenotypes of the two groups were retrospectively studied. The patients in both groups were followed up, and the overall reaction rate (OR), progress-free survival (PFS) and overall survival (OS) were calculated.  Results  The expression rates of CD33, CD7, CD56 and CD38 in the FLT3-ITD+group were significantly higher than those in the FLT3-ITD- group (all P < 0.05). By contrast, the expression rates of CD13 and CD34 were low (all P < 0.05). White blood cell count, haemoglobin count, bone marrow leukaemia cells and mutation rate of combined NPM1 in the FLT3-ITD+ group were higher than those in the FLT3-ITD- group (all P < 0.05). after the treatment the Objective response rate in the FLT3-ITD- group (78.5%) was significantly higher than that in the FLT3-ITD+ group (33.3%), and the difference was statistically significant (P < 0.001). The median OS and PFS in the FLT3-ITD+ group were 9.5 and 9 months, respectively, and those in the FLT3-ITD- group were 17 and 16 months, respectively. The OS and PFS of the FLT3-ITD- group were longer than those of the FLT3-ITD+ group (P < 0.05).  Conclusion  Patients with AML with FLT3-ITD+ have abnormal expression of leukaemia cell antigen, high peripheral blood leukocytes, abundant haemoglobin and bone marrow primordial cells, are prone to NPM1 mutation, have shortened PFS, OS and reduced the response rate. Hence, the treatment effect and prognosis of these patients are poor.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    YOUNG A L, TONG R S, BIRMANN B M, et al. Clonal haematopoiesis and risk of acute myeloid leukemia[J]. Haematologica, 2019, 104(12): 175-185. http://www.sciencedirect.com/science/article/pii/S152169261930043X
    [2]
    周文华, 陈国安. t(8;21)急性髓系白血病预后因素研究进展[J]. 中华实用诊断与治疗杂志, 2019, 33(2): 197-200. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201902028.htm
    [3]
    HE Y, SUN L, XU Y, et al. Combined inhibition of PI3Kδand FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia[J]. Cancer Lett, 2018, 420(4): 49-59. http://europepmc.org/abstract/MED/29409989
    [4]
    沈悌, 赵永强. 血液病诊断及疗效标准[M]. 4版. 北京: 科学出版社, 2018: 91-93.
    [5]
    INFANTE M S, PIRIS M Á, HERNÁNDEZ-RIVAS J Á. Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications[J]. Med Clin, 2018, 151(9): 362-367. doi: 10.1016/j.medcli.2018.05.002
    [6]
    PAPAEMMANUIL E, GERSTUNG M, BULLINGER L, et al. Genomic classification and prognosis in acute myeloid leukemia[J]. N Engl J Med, 2016, 374(23): 2209-2221. doi: 10.1056/NEJMoa1516192
    [7]
    SAKAGUCHI M, YAMAGUCHI H, KUBOYAMA M, et al. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia[J]. Int J Hematol, 2019, 110(5): 566-574. doi: 10.1007/s12185-019-02720-z
    [8]
    CHOI E J, LEE J H, PARK H S, et al. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia[J]. Leuk Res, 2018, 68(3): 51-56. http://europepmc.org/abstract/MED/29544132
    [9]
    PASIC I, DANA W, LAM W, et al. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML[J]. Eur J Haematol, 2019, 102(4): 368-374. doi: 10.1111/ejh.13216
    [10]
    DOHNER H, ESTEY E, GRIMWADE D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. doi: 10.1182/blood-2016-08-733196
    [11]
    KUROSAWA S, YAMAGUCHI H, YAMAGUCHI T, et al. The prognostic impact of FLT3-ITD, NPM1 and CEBPA in cytogenetically intermediate-risk AML after first relapse[J]. Int J Hematol, 2020, 102(4): 368-374. doi: 10.1007/s12185-020-02894-x?utm_medium=other&utm_content=null&utm_campaign=BSCN_1_DD01_CN_springer_article_paid_XMOL
    [12]
    罗丽卿, 彭振翼, 刘晓, 等. IDH2基因突变对急性髓系白血病患者的临床特征及预后影响[J]. 中国实验血液学杂志, 2019, 27(4): 1077-1082. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201904018.htm
    [13]
    ZHI H C, KAI H C, LEI T, et al. clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5[J]. Cancer Gene Ther, 2018, 25(4): 77-83. http://www.nature.com/articles/s41417-018-0013-6
    [14]
    郑源海, 林元峰, 许瑞元, 等. 急性髓系白血病免疫表型特征与预后相关性分析[J]. 现代检验医学杂志, 2018, 33(4): 90-94. doi: 10.3969/j.issn.1671-7414.2018.04.024
    [15]
    BRAS A E, DE H V, VAN S A, et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping[J]. Cytometry B Clin Cytom, 2019, 96(2): 134-142. doi: 10.1002/cyto.b.21745
    [16]
    林婧祎, 张宇晶, 高锦程, 洪珞珈. 急性髓系白血病免疫治疗方式及研究进展[J]. 中华全科医学, 2017, 15(10): 1763-1767. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201710039.htm
    [17]
    SCHRANZ K, HUBMANN M, HARIN E, et al. Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia[J]. Oncotarget, 2018, 9(53): 30128-30145. doi: 10.18632/oncotarget.25729
    [18]
    ZHANG Q R, WU X, CAO J, et al. Association between increased mutation rates in DNMT3A and FLT3-ITD and poor prognosis of patients with acute myeloid leukemia[J]. Exp Ther Med, 2019, 18(4): 3117-3124. http://www.ncbi.nlm.nih.gov/pubmed/31572552
    [19]
    刘铁强, 黄珊, 姚波, 等. 伴CD4、CD7表达的AML患者免疫表型特点及其分子生物学和细胞遗传学特征[J]. 中国实验血液学杂志, 2016, 24(6): 1627-1632. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201606006.htm
    [20]
    TAO S D, WANG C L, CHEN Y, et al. Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics[J]. Oncol Lett, 2019, 18(6): 6766-6774. http://www.ncbi.nlm.nih.gov/pubmed/31807186
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (273) PDF downloads(4) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return